RSV Antibody Shot for Newborns Linked to Reduced Bacterial Infections
A study involving nearly 530,000 French infants has found that the RSV antibody shot, nirsevimab, is associated with a 36% reduction in hospitalizations for invasive pneumococcal disease. This finding suggests an unexpected benefit of the RSV shot, which is primarily used to protect against respiratory syncytial virus. The study, published in The Lancet Infectious Diseases, highlights the potential for existing vaccines to offer additional health benefits beyond their intended use. However, the study is observational and does not establish causation, indicating the need for further research to confirm these findings.